RU58841 and some major questions? 1/11/2024
A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Apart from Finasteride, Minoxidil, and Microneedling what are you doing to reverse balding?
Various treatments for hair loss include minoxidil injections, finasteride, dutasteride, microneedling, Nizoral shampoo, and supplements like vitamin D and biotin. Additional methods mentioned are red light therapy, scalp massages, lifestyle changes, and hair transplants.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community GT20029 and PP405 the new fin and min that we been waiting for ?
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
community 9 month update - no improvement so far. Are my chances of regrowth slim at this point?
A 35-year-old has seen no hair regrowth after 9 months using treatments including finasteride, pyrilutamide, microneedling, ketoconazole shampoo, and topical dutasteride, but experienced side effects with RU58841. Commenters suggest starting minoxidil for better results and question why it wasn't included from the beginning.
community Comprehensive list of Hair loss treatments and your opinion on the best combination to us.
The conversation discusses using oral Minoxidil, topical Minoxidil with RU58841, Finasteride, and serioxyl for hair loss. It also asks for opinions on the effectiveness of other treatments like Setipiprant, Dutasteride, and Spironolactone, and thoughts on HMI-115 and GT20029 trials.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Investigational medications in the treatment of alopecia
This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.
research Minoxidil: effectiveness and prospects for use in the treatment of androgenetic alopecia
Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.
research Тіе Modern treatment of androgenetic alopecia
This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
research Андрогенетическая алопеция: патогенетические механизмы и подходы к лечению
This article reviews the pathophysiology and limited effectiveness of current treatments for androgenic alopecia, including finasteride, minoxidil, botulinum toxin A, and platelet-rich plasma, and highlights the need for new therapeutic approaches; it reports no new clinical findings.